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SUMMARY
We previously isolated a 1.3-kb genomic fragment in the 59-
flanking region of the murine neuropeptide Y (NPY) Y1 receptor
gene, which is able to drive the expression of LacZ reporter
gene in neuronal cells. We determined the ability of deletion
mutants of this region to modulate transcription of the heterol-
ogous luciferase gene in the Y1 receptor-expressing neuroblas-
toma/glioma NG108-15 cells and the Y1 receptor-deficient 293
cells. Results suggest the presence of a cell type-specific core
promoter (2399 to 2218 from the initiator ATG) and, upstream,
of two positive and two negative regulatory elements. Se-
quence analysis of the Y1 receptor promoter identified two
decameric sequences corresponding to consensus binding
sites for nuclear factor-kB/Rel proteins. Gel shift analysis indi-
cated that a 29-bp oligonucleotide comprising the two putative
kB sites, which we refer to as Y1-kB sequence, specifically
binds kB-related complexes in nuclear extracts from rat brain
areas, NG108-15 cells, and the murine T cell clone A.E7. In
nuclear extracts from A.E7 and NG108-15 cells, the Y1-kB
sequence specifically binds an additional complex whose mo-
lecular nature remains to be elucidated. Through transient
transfection studies, we also demonstrated that the Y1-kB se-
quence acts as an enhancer element, inferring its potential role
in regulation of the Y1 receptor gene expression.
NPY is the most abundant and widely distributed neu-
ropeptide within the central nervous system, where it par-
ticipates in the control of a large number of physiological
functions, including effects on food intake, psychomotor ac-
tivity, and central endocrine secretion and potent vasoactive
effects on the cardiovascular system (1, 2). Two major sub-
types of NPY receptors, Y1 and Y2, have been defined on the
basis of pharmacological criteria; the Y1 receptor is consid-
ered to be a postjunctional receptor, and the Y2 receptor is
considered to be a prejunctional receptor (3). We and others
previously reported the molecular cloning of the Y1 receptor
cDNA from rat (4, 5), mouse (6), and human (7, 8) tissues; its
primary structure shows that it belongs to the superfamily of
G protein-coupled receptors. In peripheral tissues, the Y1
receptor is found predominantly at the sympathetic postjunc-
tional sites in blood vessels, where it mediates the contractile
response to NPY of vascular smooth muscle, both directly
and indirectly by potentiating the action of other pressure
agents, such as norepinephrine (3). In the central nervous
system, the Y1 receptor has been linked with different phys-
iological processes, including stimulation of feeding behavior
(9), stimulation of luteinizing hormone-releasing hormone
release (9), a sedative anxiolytic effect (10, 11), and modula-
tion of inflammation and nociception (12, 13).
Recent studies have shown that a marked plasticity in the
expression of the Y1 receptor and its mRNA can be induced
under different circumstances. For example, peripheral tis-
sue inflammation evokes up-regulation of Y1 receptor mRNA
in dorsal root ganglia; in the same tissue, peripheral axotomy
changes expression of the Y1 receptor mRNA level (12, 13).
The molecular mechanisms responsible for regulation of Y1
receptor expression are unknown; however, like the mecha-
nisms for b2 receptors and other G protein-coupled receptor
genes (14–16), they may result from alteration of the tran-
scriptional regulatory pathway.
We recently cloned the murine gene of the Y1 receptor, and
we isolated a 1.3-kb genomic fragment of the 59 flanking
region that is able to drive the expression of the lacZ reporter
gene in the mouse neuroblastoma/rat glioma NG108-15 cell
line and in rat corticostriatal neuron primary cultures but
not in the Y1 receptor-deficient rat glial and human embry-
onic kidney 293 cells (6). Sequence analysis of this region
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revealed the presence of several potential recognition se-
quences for known transcription factors, including two
decameric sequences corresponding to consensus sites for
members of the NF-kB/Rel family of transcription factors,
three AP-1 sites, three half-palindromic estrogen-responsive
elements, and one cAMP-responsive element (Fig. 1A).
In the current study, we further characterized the up-
stream promoter region of the murine Y1 receptor gene
through the use of transient transfection assays with
NG108-15 and 293 cells. Analysis of Y1-R/LUC constructs
containing deletions of the Y1 receptor regulatory region
suggested the presence of a 181-bp cell type-specific core
promoter spanning nucleotides 2399 through 2218 from the
initiator ATG and, upstream of this region, of two positive
and two negative regulatory elements. Furthermore, we
present evidence that members of the NF-kB/Rel family of
transcription factors may participate in regulation of the Y1
receptor gene expression. The functional role of this family of
inducible, ubiquitous transcription factors has been widely
characterized in the periphery, where these proteins respond
to a variety of signals and control expression of several genes
mainly implicated in inflammatory and immune reactions
(for reviews, see Refs. 17–19). More recently, several groups
have shown that NF-kB is also abundant in brain, where it
was found as both an inducible and a constitutively activated
form (20–27). However, currently, very little is known about
the role of NF-kB-related factors in regulation of the expres-
sion of genes whose products play a functional role in the
central nervous system.
Materials and Methods
Cell culture. The mouse neuroblastoma/rat glioma NG108-15
cells were plated onto Falcon Petri dishes coated with 10 mg/ml
poly-L-lysine (Mr 70–150 3 10
3) and were cultured in the minimum
essential medium containing 10% fetal bovine serum and 13 HAT
supplement (all from GIBCO, Grand Island, NY). The human em-
bryonic kidney 293 cells were grown in minimum essential medium
and 10% fetal bovine serum. Mouse fibroblast NIH 3T3 cells were
cultured in Dulbecco’s modified Eagle’s medium containing 10% calf
serum (GIBCO). All culture media contained 2 mM glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin.
Plasmid construction. A SalI/BglII fragment from the original
murine Y1 receptor genomic clone (from nucleotides 21523 to 2218
relative to the initiator ATG) was first subcloned into the polylinker
of pBluescript SK2 (Stratagene, La Jolla, CA) (6) (Fig. 1B). The
SalI/BglII fragment was isolated by gel electrophoresis; then, the
BglII-digested end (all restriction enzymes were from Boehringer-
Mannheim Biochemicals, Indianapolis, IN) was filled in with the
Klenow fragment of DNA polymerase I (Boehringer-Mannheim) and
excess of dNTPs (0.4 mM). The resulting SalI-blunt fragment was
ligated into the SalI/ClaI sites of pBluescript SK2 after the ClaI site
of the plasmid was filled to obtain a blunt end. This construct
(pBS-Y1PR) contains 1305 bp of the 59 flanking region of the murine
Y1 receptor gene and includes the first three sites of initiation of
transcription (6). The Y1R-LUC expression plasmids were con-
Fig. 1. Murine Y1R-LUC expres-
sion plasmids. A, Putative cis-act-
ing elements residing in the up-
stream region of the murine Y1
receptor gene. Above each box,
relative position of the proximal
nucleotide in each motif in rela-
tion to the initiator ATG. Below
each box, nucleotide sequences.
ERE, estrogen-responsive ele-
ment; CRE, cAMP-responsive el-
ement. Underlined, sequences in
the Y1-kB motif corresponding to
the kB site. B, Luciferase fusion
constructs containing deletion
fragments of the murine Y1 recep-
tor 59 flanking region. Top, restric-
tion fragments that were used for
deletion mutants.
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structed through subcloning into the polylinker of pGL2-basic (Pro-
mega, Madison, WI) with the following restriction fragments from
pBS-Y1PR: a 1305-bp SalI/HindIII fragment (p1305-LUC), a 985-bp
HpaI/HindIII fragment (p985-LUC), a 686-bp SmaI/HindIII frag-
ment (p686-LUC), a 618-bp NsiI/HindIII fragment (p618-LUC), a
490-bp SspI/HindIII fragment (p490-LUC), a 306-bp PstI/HindIII
fragment (p306-LUC), and a 181-bp EcoRI/HindIII (p181-LUC) frag-
ment (see Figs. 1B and 2B). Constructs containing an upstream
sequence between nucleotides 21113 and 2960 (p895-LUC, p876-
LUC, p808-LUC, and p742-LUC; see Figs. 1B and 2B) were obtained
through digestion of pBS-Y1PR withHpaI and subsequent treatment
with Bal31 enzyme (Boehringer-Mannheim). The plasmid DNA was
then rendered blunt with the Klenow enzyme, digested a second time
with HindIII, and subcloned into the SmaI/HindIII sites of pGL2-
basic. The junctions between the insert DNAs and luciferase gene of
the fusion constructs were confirmed through sequence analysis (28).
Oligonucleotides containing the Y1-kB and mY1-kB (see below)
were synthesized with BglII overhangs, annealed, and inserted into
the BamHI site of pBluescript SK2, resulting in kB-pBS SK2 and
mkB-pBS SK2.
To construct pkB-985-LUC, pkB-686-LUC, pmkB-686-LUC, and
pkB-181-LUC plasmids, the deletion fragments of the Y1 receptor 59
flanking sequence were obtained from pBS-Y1PR using the unique
HindIII site from the pBluescript SK2 polylinker and the appropri-
ate restriction sites in the upstream region of Y1 receptor gene and
were ligated immediately downstream of the wild-type and mutated
kB sites of kB-pBS SK2and mkB-pBS SK2. The resulting plasmids
were digested by XbaI, rendered blunt by Klenow enzyme, digested
a second time with HindIII, and subcloned into the SmaI/HindIII
sites of the pGL2-basic vector (see Fig. 2B). To obtain the pkB-893-
LUC, pkB-873-LUC, pkB-811-LUC, and pkB-741-LUC plasmids, the
pkB-686-LUC plasmid was digested by SmaI/HindIII to remove the
696-bp insert, resulting in kB-pGL2. The plasmid pBS-Y1PR was
then digested with HpaI and subsequently treated with Bal31 en-
zyme. The plasmid DNA was rendered blunt by Klenow enzyme,
digested a second time with HindIII, and ligated into the SmaI/
HindIII sites of kB-pGL2 (see Fig. 2B). The sequences of the result-
ing kB/Y1R-LUC expression plasmids were confirmed through re-
striction analysis and nucleotide sequence determination.
Sequencing of the Y1R-LUC expression plasmids revealed seven
nucleotide errors compared with the previously published 59 flanking
region of the Y1 receptor gene.
1
Transient transfection experiments. Transfection of reporter
plasmids into NG108-15, 293 and NIH 3T3 cells was performed
according to the calcium phosphate coprecipitation method (29). In
all experiments, pSV-b-galactosidase control vector (Promega), con-
taining the b-galactosidase gene linked to the simian virus 40 early
1 The corrected DNA sequence is in the EMBL/GenBank database (acces-
sion No. Z18281).
Fig. 2. kB-Y1R-LUC expression
plasmids. A, Putative regulatory
elements residing in the 59 flank-
ing region of the Y1 receptor
gene. B, kB-Y1R-LUC fusion
genes containing the Y1-kB motif
ligated immediately upstream of
different deletion fragments of the
murine Y1 receptor promoter.
Above each kB-Y1R-LUC plas-
mid, corresponding luciferase fu-
sion constructs containing the
deletion fragments of the murine
Y1 receptor 59 flanking region.
Mutant constructs were obtained
as described in Materials and
Methods and were confirmed by
sequence analysis and restriction
mapping. Restriction fragments
that were used for deletion mu-
tants are shown in Fig. 1.
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promoter/enhancer, was included as an internal control for the dif-
ferent transfection efficiencies between experiments. When cells
reached ;50% confluence, each 35-mm Petri dish received equimolar
amounts (2.5 mg) of test plasmid and pSV-b-galactosidase. Cells were
harvested 48 hr after transfection, and the activities of luciferase and
b-galactosidase were assayed as previously described (30). As con-
trols, the plasmid pGL2-basic, containing the promoterless luciferase
gene, and the plasmid pGL2-promoter vector (Promega), containing
the luciferase gene driven by the simian virus 40 promoter, were
transfected into parallel cultures of each cell line. In all of the cell
lines tested, the pGL2-basic was inactive, whereas the pGL2-pro-
moter vector showed high levels of luciferase activity.
Pharmacological treatments of transiently transfected NG108-15
cells were performed 8 and 20 hr before processing of cells.
Nuclear extracts and electrophoretic mobility shift assays.
Nuclear extracts from rat brain areas were prepared essentially as
described by Kang et al. (31). Nuclear extracts from cell lines and
from A.E7 cells were prepared according to a small-scale protocol
(25) with minor modifications. Briefly, 5–10 3 106 cells were scraped
into cold phosphate-buffered saline, washed once in phosphate-buff-
ered saline, and pelleted for 10 sec in an Eppendorff centrifuge. Cells
were then resuspended in 400 ml of cold buffer A (10 mM HEPES-
KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM
phenylmethylsulfonyl fluoride), allowed to swell on ice for 10 min,
and vortexed for 10 sec. Samples were centrifuged for 10 sec, and the
pellets were resuspended in 50 ml of cold buffer C (20 mM HEPES-
KOH pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 0.2 mM phenylmethylsulfonyl fluoride) and
incubated on ice for 20 min for high salt extraction. Cellular debris
were removed by centrifugation for 2 min at 4°, and the supernatant
was stored at 270°. Protein concentration was assessed by BioRad
(Hercules, CA) Bradford assay according to the manufacturer’s in-
structions. DNA binding reaction were initiated by the combination
of 2 mg of nuclear extracts with 20,000 cpm (0.1 ng) of g-32P-labeled
oligonucleotide probes in 13 lipage buffer (10 mM TriszHCl, pH 7.5,
50 mMNaCl, 1 mM DTT, 1 mM EDTA, 10% glycerol) containing 0.5 mg
of poly(dI/dC) in a total volume of 10 ml. In competition experiments,
indicated amounts of unlabeled competitor oligonucleotides were
added with 32P-labeled probes. Reactions were carried out for 20 min
at room temperature, and protein/DNA complexes were resolved on
nondenaturing 4% polyacrylamide gels in 13 Tris/glycine/EDTA
buffer (13 5 50 mM Tris, 380 mM glycine, and 2.7 mM EDTA). Gels
were then dried and subjected to autoradiography at room temper-
ature.
Synthetic DNA oligonucleotides. Oligonucleotide sequences
and their respective complementary strands were synthesized with a
DNA synthesizer (Applied Biosystems, Norwalk, CT) and purified
through denaturing gel electrophoresis. Oligonucleotides were an-
nealed to complementary strands by heating to 68° and cooling
slowly to room temperature. For gel shift analysis, double-stranded
oligonucleotides were end-labeled with [g-32P]ATP (. 7000 Ci/mmol;
ICN Pharmaceuticals, Costa Mesa) and T4 polynucleotide kinase
(Boehringer-Mannheim) to obtain a specific activity of .108 cpm/mg.
The sequences of the oligonucleotides were as follows: Y1-kB, 59-
GATCATGGGATTTCATTGGGATTTCACTT-39 (sense); mY1-kB, 59-
GATCCATctcATTTCATTctcATTTCACTT-39 (sense); Ig-kB, 59-CA-
GAGGGGACTTTCCGAGAGGC-39; and octamer (octamer binding
site from the IL-2 gene enhancer region), 59-TATGTGTAATATGTA-
AAACATTTTGACACC-39. Sequences corresponding to the kB site
are underlined.
Statistical analysis. Statistical analysis was performed by using
the Mann-Whitney U test.
Results
Analysis of the effect of progressive deletion within
the Y1 receptor promoter on heterologous gene expres-
sion. The ability of several deletion mutants of the 59 flank-
ing region of the murine Y1 receptor gene to drive the expres-
sion of the luciferase reporter gene was analyzed in transient
transfection experiments. As shown in Fig. 3, the 1.3-kb
genomic fragment, spanning nucleotides 21523 through
2218 relative to the initiator ATG (p1305-LUC), drives the
luciferase activity in NG108-15 cells, whereas a very low
enzyme activity was determined in 293 cells. Sequential de-
letion from nucleotides 21523 through 21026 (p985-LUC,
p895-LUC, p876-LUC, and p808-LUC) had no significant
effect on luciferase activity (Figs. 3 and 4). Further deletion
to nucleotide 2960 (p742-LUC) resulted in an ;2-fold in-
crease in luciferase activity in NG108-15 cells but not in 293
cells, suggesting the presence of a negative regulatory ele-
ment between nucleotides 21026 and 2960 that is operative
in NG108-15 cells. The promoter activity remained un-
changed by removal of the region between 2960 and 2904
(p686-LUC), whereas further reduction of the upstream se-
quence to nucleotide 2836 (p618-LUC) increased the lucif-
erase activity by ;2-fold in NG108-15 cells but not in 293
Fig. 3. Deletion analysis of the murine Y1 receptor gene promoter. The
promoter activity of the Y1R-LUC expression plasmids was determined
in (open bars) NG108-15 and (hatched bars) 293 cells. Left, tested
reporter plasmids. The luciferase activity was normalized to b-galacto-
sidase activity obtained by cotransfecting cells with the control plasmid
pSV-b-galactosidase (in cpm). Values are mean 6 standard error from
eight or more transfection experiments, each performed in triplicate,
with plasmid DNAs from at least two different preparations. Cultures
transfected with the promoterless plasmid pGL2-basic had a mean
luciferase activity of 0.16 6 0.018 and 0.04 6 0.003 cpm 3 1026 in
NG108-15 and 293 cells, respectively.
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cells, suggesting that the sequence between nucleotides 2904
and 2836 contains a negative regulatory element that con-
tributes to lower Y1 receptor gene expression in this cell type
(Fig. 3). Further deletion to nucleotide 2708 (p490-LUC)
decreased the luciferase activity to the level driven by the
undeleted Y1 receptor promoter (p1305-LUC) in NG108-15
cells, suggesting the presence of a positive cis-acting element
between nucleotides 2836 and 2708. Extension of 59 deletion
to nucleotide 2524 (p306-LUC) did not affect the luciferase
activity significantly, whereas further deletion to nucleotide
2399 (p181-LUC) reduced the reporter gene expression by
2.8-fold in NG108-15 cells, suggesting the presence of a pos-
itive cis-acting element between nucleotides 2524 and 2399.
The remaining 181 bp-genomic fragment, spanning nucleo-
tides 2399 and 2218 of the Y1 receptor gene, drives the
luciferase activity in NG108-15 cells at a level significantly
above the pGL2-basic (see legend to Fig. 3), indicating that it
represents the minimal promoter region still capable of di-
recting expression of the Y1 receptor gene in the neuroblas-
toma/glioma cell line. It should also be pointed out that the
same sequence is unable to drive luciferase activity in 293
cells. Furthermore, all of the Y1 receptor deletion mutants/
fusion constructs drove negligible luciferase activity when
transiently transfected into the mouse fibroblast NIH 3T3
cell line (data not shown).
Binding of Y1-kB sequences to members of the family
of NF-kB transcription factors. Detailed sequence analy-
sis of the Y1 receptor promoter region reveals the presence of
putative binding sites for known transactivating factors that
may play a role in the regulation of the tissue-specific expres-
sion of this gene (Fig. 1A). Particularly, we focused our in-
terest on the sequence located in position 21302 through
21282 in the Y1 receptor gene regulatory region because it
contains two decameric sequences corresponding to consen-
sus sites for members of the NF-kB/Rel family of transcrip-
tion factors (6). We performed experiments to verify whether
the aforementioned sequences are indeed binding sites for
transcriptional control proteins belonging to this family. A
well-studied model of gene regulation mediated by kB/Rel
proteins is represented by A.E7 cells, a CD41 murine T cell
clone in which kB-mediated gene expression has been exten-
sively analyzed. Kang et al. (31) demonstrated that these
untransformed cells constitutively express at least two nu-
clear complexes belonging to the NF-kB/Rel family: the p50-
p65 (relA) heterodimer and the p50 homodimer. In this well-
characterized model, we initially studied binding properties
of the putative kB sequences from the Y1 receptor gene.
An oligonucleotide comprising the two kB sequences from
the Y1 receptor gene (Y1-kB oligonucleotide) was synthesized,
radioactively labeled at the 59 end with T4 kinase, and incu-
bated with nuclear extracts prepared from A.E7 cells. Sub-
Fig. 4. Enhancer activity of the Y1-kB sequence in NG108-15 cells.
Histograms show the mean 6 standard error of at least eight transfec-
tion experiments, each performed in triplicate. Each reporter plasmid
tested (left) was independently prepared at least two times. The lucif-
erase activity was normalized to b-galactosidase activity from a co-
transfected internal control plasmid pSV-b-galactosidase (in cpm). The
luciferase activity of pkB-741-LUC, pkB-686-LUC, and pkB-181-LUC
was significantly more than that of p742-LUC, p686-LUC, and p181-
LUC, respectively (p, p , 0.05).
Fig. 5. Analysis of the binding properties of the Y1-kB sequence on
nuclear extracts from a T cell clone endowed with constitutive NF-kB/
Rel activities and on the p50 subunit. A, Oligonucleotide sequence
comprising the two kB sequences from the Y1 receptor gene (Y1-kB)
binds three specific nuclear complexes in extracts from a murine T cell
clone, A.E7. Electrophoretic mobility shift assay obtained through in-
cubation of 2 mg of A.E7 nuclear extracts with 32P-labeled Y1-kB probe
in the absence (0 ng) or in the presence of 1, 16, or 32 ng of unlabeled
Y1-kB or Ig-kB as competitors. B, Affinity purified, bacterially produced
p50 subunit of the NF-kB/Rel family can bind the Y1-kB oligonucleotide
probe. bp50, bacterially purified p50.
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sequently, binding reactions were analyzed in a gel shift
assay; results are shown in Fig. 5A. The Y1-kB probe could
detect three nuclear complexes with different migration
properties. All complexes proved to result from specific inter-
action with the DNA sequence because they were displaced,
in a dose-dependent manner, by the unlabeled oligonucleo-
tide Y1-kB. To further analyze the relationship between these
nuclear complexes and NF-kB/Rel proteins, an oligonucleo-
tide sequence containing a classic kB site (Ig-kB) was tested
for the ability to compete for binding to the Y1-kB oligonu-
cleotide. As shown in Fig. 5A, only the top two migrating
complexes were competed, whereas the binding of the third
complex was unaffected. These results suggested that the
two higher-molecular-weight complexes able to bind the
Y1-kB sequence were indeed kB-related proteins, whereas
the third complex, which was present in nuclear extracts
from A.E7 cells, was also able to specifically bind the exam-
ined sequence, but as shown by the results of the competition
analysis with the Ig-kB oligonucleotide, we could exclude
that it was a kB-related protein or even a degradation prod-
uct of the higher-molecular-weight kB complexes. To further
prove the ability of the Y1-kB sequence to bind kB-related
complexes, we confirmed that bacterially expressed, affinity
purified p50 protein, one of the members of the NF-kB/Rel
family, was indeed able to bind the Y1-kB probe in a gel shift
assay (Fig. 5B).
Nuclear extracts were also prepared from NG108-15 cells
and tested in a gel shift assay for binding to the 32P-labeled
Y1-kB sequence. In analogy with what we observed in A.E7
extracts, three retarded complexes were detected (Fig. 6A,
lane 1). When the same extracts were incubated with the
Ig-kB oligonucleotide probe, two complexes were detected,
comigrating with the top two complexes bound to the Y1-kB
probe (Fig. 6A, lane 2). A detailed competition analysis of the
Y1-kB bound complexes was performed (Fig. 6B). Increasing
amounts (1–8 ng) of unlabeled Y1-kB oligonucleotide (lanes
2–4) and Ig-kB (lanes 5–7) were used. The two higher-molec-
ular-weight complexes were displaced by both competitors,
whereas binding of the third complex seemed to be affected
by the Y1-kB but not by the Ig-kB oligonucleotide. None of the
complexes were competed by an unrelated oligonucleotide
containing the octamer protein binding site (lanes 9–12),
even when a higher concentration (16 ng) of competitor was
used (lane 12).
Interaction between the Y1-kB sequences and DNA-bind-
ing factors was further investigated in nuclear extracts from
several rat brain regions, including cortex, hippocampus,
striatum, cerebellum, and olfactory bulb. Results of a repre-
sentative gel shift assay are shown in Fig. 7. Surprisingly, in
this situation, a single DNA binding activity was detected,
which seemed to be specific because it could be competed by
unlabeled Ig-kB sequence [Fig. 7, lane 6, shows competition
on nuclear extracts from rat cortex, but the same results
were obtained with extracts from the other rat brain regions
(not shown)].
The Y1-kB oligonucleotide sequence from the Y1 re-
ceptor gene acts as enhancer element in NG108-15
cells. Although the deletion from nucleotides 21523 to
21203 (p985-LUC) in the Y1 receptor sequence did not affect
luciferase activity in our in vitro model (Fig. 4), based on the
essential role of the NF-kB/Rel family of transcription factors
for the expression of several genes (for reviews, see Refs.
17–19), we surmised that the Y1-kB sequence may partici-
pate in the regulation of the transcriptional activity of this
gene. To test this possibility, we constructed a series of ex-
pression plasmids (pkB-Y1R-LUC) in which an oligonucleo-
tide corresponding to the Y1-kB sequence was placed imme-
diately upstream of deletion fragments of the Y1 receptor 59
flanking region that did not contain the endogenous sites
(Fig. 2B). Results indicated that the Y1-kB sequence, when
placed upstream of nucleotides 2959, 2904, and 2399 from
the initiator ATG (pkB-741-LUC, pkB-686-LUC, and pkB-
181-LUC, respectively), enhances by .2-fold the luciferase
activity in NG108-15 cells (Fig. 4). Specificity of the effect
was demonstrated by the fact that mutation of selected nu-
cleotides within the motifs, which abolished binding activity
in gel shift assay (not shown), completely abolished enhancer
activity (Fig. 8). Interestingly, the Y1-kB sequence seemed to
be functional in NG108-15 cells but not in 293 cells (Fig. 8).
Furthermore, the Y1-kB motif failed to increase luciferase
activity when placed upstream of nucleotides 21203 (pkB-
985-LUC), 21111 (pkB-893-LUC), 21091 (pkB-873-LUC),
and 21029 (pkB-811-LUC) suggesting that the 70-bp se-
quence spanning nucleotides 21029 and 2959 of the Y1
receptor promoter contains a negative regulatory element
that inhibits Y1-kB enhancer activity in NG108-15 cells (Fig.
4). The kB-related factors were found as both inducible and
constitutively activated complexes in the central nervous
system (20–27). The kB nuclear activity interacting with the
Y1 receptor gene is constitutive. We verified whether specific
extracellular signals might further activate the enhancer
Fig. 6. Gel shift analysis of nuclear complexes specifically interacting
with the Y1-kB probe in NG108-15 cell extracts. A, Comparison of the
migration properties of complexes intercepted by (lane 1) Y1-kB and
(lane 2) Ig-kB oligonucleotide probes in NG108-15 cell extracts. B,
Competition analysis of the complexes bound by the Y1-kB oligonu-
cleotide probe. Competition was performed by adding the indicated
amounts (in ng) of the unlabeled oligonucleotide sequences Y1-kB
(lanes 2–4) or Ig-kB (lanes 5–7) or the unrelated oligonucleotide se-
quence for octamer binding proteins (lanes 9–12). 2, No competitor
(lanes 1 and 8). Apparent discrepancies in the migration properties of
complexes in A and B are due to differences in gel running length in the
two different sets of experiments.
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activity of the Y1-kB sequence. To investigate this possibility,
we treated NG108-15 cells transfected with pkB-686-LUC or
pkB-181-LUC plasmids with various agents that are known
to modulate activity of these transcriptional regulators in
either peripheral or central nervous system-derived cells (17,
22, 25–27). In particular, we tested cytokines, such as IL-1
(30 units/ml), IL-2 (2 nM), and tumor necrosis factor-a (100
ng/ml); lipopolysaccharide (25 mg/ml); concanavalin A (25
mg/ml); 12-O-tetradecanoylphorbol-13-acetate (0.1 mM); hy-
drogen peroxide (50 and 100 mM), KCl (30 mM); and gluta-
mate (100 mM). However, none of these agents were able to
further augment the transcriptional activity of pkB-686-LUC
or pkB-181-LUC expression plasmids (data not shown).
Discussion
The Y1 receptor subtype plays important roles in mediat-
ing NPY-induced control of several functions, including car-
diovascular system activity, neuroendocrine secretion, food
intake, and nociception (1, 2). In situ hybridization studies
have shown that Y1 receptor mRNA is indeed highly ex-
pressed in several regions of the rat forebrain, in the hypo-
thalamus, and in dorsal root ganglia (4, 13, 32, 33). We
previously isolated the murine gene encoding the Y1 receptor
and demonstrated that the 59 flanking region of this gene
contains a functional promoter that is active in neuronal cells
(primary cultured neurons and NG108-15 cells) but not in
glial or 293 cells (6).
In the current study, we investigated which regions of the
Y1 receptor promoter contain potential negative or positive
cis-acting elements participating in the regulation of gene
expression. For this purpose, luciferase constructs compris-
ing the 1.3-kb 59 flanking regions of the Y1 receptor or vari-
ous 59 deletions of it were transfected into a cell line that
expresses the Y1 receptor endogenously, NG108-15 cells, and
in the Y1 receptor-deficient 293 cell line. Deletional analysis
has shown the presence of several potential areas of tran-
scriptional regulation. Our data suggest the presence of at
least two positive acting regulatory elements lying between
nucleotides 2836 and 2708 and between nucleotides 2524
and 2399. Although the sequence of the fragment contained
between 2836 and 2708 has no clear homology to any known
regulatory element, it is noteworthy that an AP-1 binding
site resides between nucleotides 2473 and 2479. Further
mutational and deletional analysis will be required to define
whether this site functions as a cis-acting element. In pre-
liminary experiments, we were able to show that the Y1
receptor promoter/luciferase reporter gene can be positively
modulated by treatment with phorbol esters but that deletion
of the sequence containing the AP-1 site (2473 to 2479) fails
to suppress this type of responsiveness (data not shown).
Fig. 7. The Y1-kB oligonucleotide sequence binds a single kB-related
complex in nuclear extracts from several rat brain regions. Protein
extracts were from hippocampus (lane 1, hipp.), striatum (lane 2),
cerebellum (lane 3, cereb.), cortex (lanes 4 and 6), and olfactory bulb
(lane 5, olf. bulb). Lane 6, binding competition was performed with 16
ng of the unlabeled oligonucleotide Ig-kB and nuclear extracts from
cortex.
Fig. 8. Mutational analysis of the Y1-kB sequence. A three-nucleotide
mutation was made in each kB motif from the Y1-kB oligonucleotide
sequence as described in Materials and Methods. The pmkB-686-LUC
fusion plasmid was prepared by ligating the mutated Y1-kB motif
(mY1-kB) immediately upstream of the 686-bp (SmaI/HindIII) deletion
fragment of the Y1 receptor promoter. Promoter activity of the p1305-
LUC, p686-LUC, pkB-686-LUC, and pmkB-686-LUC was determined
in (open bars) NG108-15 and (hatched bars) 293 cells. The enhancer
activity of the mutated Y1-kB motif was depicted in NG108-15 cells. p,
p , 0.05 versus p1305-LUC. pp, p , 0.05 versus p686-LUC.
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A second type of regulation that may exist for the Y1
receptor gene expression involves silencer domains. Our
work suggests the presence of at least two negative regula-
tory elements contained between nucleotides 21026 and
2960 and between nucleotides 2904 and 2836. To assess the
cell type specificity of these sequences, 293 and NIH 3T3 cells
were transfected with the corresponding luciferase con-
structs. All deletion mutants were ineffective in modulating
transcription of the heterologous luciferase gene in these cell
lines, indicating that the negative regulatory elements of the
Y1 receptor gene are not responsible for repression in these
cell lines.
Reporter gene assay also suggested that the core promoter
(2399 to 2218) of the Y1 receptor gene exhibited substantial
cell type specificity. Ball et al. (34) recently reported that the
human Y1 receptor gene is under the control of three promot-
ers that are activated in a tissue-specific manner. It is note-
worthy that the core promoter of the murine Y1 receptor gene
displays a high sequence homology with the corresponding
region of the human promoter directing the expression of the
most abundant Y1 receptor transcript.
Detailed analysis of the sequence of the murine Y1 receptor
59 flanking region reveals the presence of many putative
binding sites for known transcription factors (6) (Fig. 1A). We
focused our attention on the murine Y1 receptor promoter
region that contains two decameric sequences located in tan-
dem in position 21302 to 21282 bp, relative to the ATG.
These sequences correspond to consensus sites for members
of the kB-Rel family of transcription factors (17). In the
current study, we showed that this sequence can indeed bind
kB-related nuclear complexes in a specific manner and acts
as an enhancer element in transiently transfected NG108-15
cells.
NF-kB/Rel proteins are constitutive and inducible tran-
scription factors that are present in most cell types. Each kB
complex corresponds to homodimers and heterodimers whose
subunits belong to a superfamily that comprises at least five
DNA binding proteins: p50, p52 (p50B), p65 (RelA), c-rel, and
RelB (17–19). The inducible form of NF-kB contains an ad-
ditional inhibitory subunit called IkB and can be activated in
response to stimuli that mostly represent pathogenic condi-
tions, including viruses, bacterial lipopolysaccharide, inflam-
matory cytokines, and oxidants. It was previously suggested
that only a limited number of lymphoid cells contain consti-
tutively active NF-kB-related factors (35, 36). More recent
evidence, however, indicates that in the central nervous sys-
tem, members of the kB family of transcription factors are
constitutively active and are present in the nucleus of cul-
tured neurons as well as in neurons in vivo (21, 24, 25).
Our data demonstrate that the Y1-kB sequence binds with
high affinity members of the kB/Rel family of transcription
factors in nuclear extracts from rat brain areas, from the
NG108-15 neuronal cell line, and from the murine T cell
clone A.E7. Interestingly, different binding properties were
observed in nuclear extracts from different sources. In nu-
clear extracts from rat brain regions, a single kB-related
complex was detected. In nuclear extracts prepared from the
cell line NG108-15, as well as in extracts from the murine T
cell clone A.E7, three complexes with different migration
properties interacted specifically with the Y1-kB sequence,
but only two of them seemed to be kB-related nuclear activ-
ities in competition experiments. The molecular nature of the
third complex, specifically interacting with the Y1-kB se-
quence, remains to be elucidated. Furthermore, detailed mu-
tation studies are necessary to better define the binding
requirements of each complex to the Y1-kB sequence contain-
ing the two kB sites. Also, it will be interesting to clarify the
significance of the differences in binding activities in rat
brain extracts compared with extracts from NG108-15 cells
and from the murine T cell clone A.E7. It is noteworthy that
the single complex identified by the Y1-kB oligonucleotide
probe in rat brain extract is reminiscent of the binding spec-
ificity of a kB-binding site recently identified and character-
ized in the regulatory region of the amyloid precursor pro-
tein, which in rat brain extracts recognizes specific
complexes that are either identical or very similar to p50
homodimers (25).
In transient transfection assays, we also demonstrated
that the Y1-kB sequence behaves as an enhancer element
when placed upstream of deletion fragments of the Y1 recep-
tor regulatory region. Surprisingly, the Y1-kB site does not
enhances the transcriptional activity of the fusion gene con-
structs when placed $70 bases upstream of nucleotide 2959
relative to the initiator ATG. These results suggest that the
70-bp region lying between 21029 and 2959 bases of the 59
flanking region of the Y1 receptor gene might contain a neg-
ative regulatory element that is able to suppress the en-
hancer activity of Y1-kB sequence in NG108-15 cells.
The NF-kB activity interacting with the Y1 receptor gene
promoter seems to be a constitutive activity, but it is well
known that these transcriptional activators can be present as
both activated and inducible forms in neurons (20, 22, 25–
27). A wide variety of stimuli can modulate NF-kB/Rel activ-
ities, depending on the cell type (17–19). However, the treat-
ment of NG108-15 cells with several agents, including
inflammatory cytokines, oxidants, bacterial lipopolysaccha-
ride, and neurotransmitters, failed to stimulate the tran-
scriptional activity of the Y1-kB sequence. It is possible that
in NG108-15 cells, the intracellular signals that activate
NF-kB proteins are coupled to specific membrane receptors
that we were unable to identify, or that in this tumoral cell
line, the Y1-kB binding activity is maximally up-regulated.
To answer these questions, we are analyzing the modulation
of the Y1-kB binding activity in primary cultures of neuronal
cells.
The results that we report are, to our knowledge, the first
demonstration that a kB-related motif contained in the reg-
ulatory region of a neuropeptide receptor gene binds kB-
related nuclear proteins and might be activated by this fam-
ily of transcription factors. The functional significance of
these data remains to be elucidated. Kaltschmidt et al. (22)
suggested that in neurons, the kB-related factors might par-
ticipate in the normal physiology and development of the
nervous system. Sequence analysis revealed the presence of
putative kB-related sequences in the regulatory region of
other neuropeptide receptor genes, such as the vasoactive
intestinal peptide receptor (37) and the d-opioid receptor (38).
It is possible that this family of transcription factors partic-
ipates in the control of neurotransmission by transcription-
ally regulating the expression of neuropeptide and neuro-
transmitter receptor genes.
In most cell types, the kB-related proteins mediate an
immediate-early response to stimuli that represent stress
conditions. Vascular responsiveness to NPY was shown to be
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increased in conditions that were occurring physiologically
during prolonged stress or in disease states, such as hyper-
tension (39). In addition, NPY seems to play a critical role in
the transmission of stress-related information to the hypo-
thalamic/hypophysial system and in the activation of neu-
roendocrine responses essential for the survival of the organ-
ism (40). An interesting possibility is that the Y1 receptor for
NPY may represent one of the kB site-containing genes that
is modulated in the mammalian nervous system by kB-re-
lated factors in response to stimuli that require an immedi-
ate defensive response.
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